Review of the relationship between renal and retinal microangiopathy in diabetes mellitus patients

Current Diabetes Reviews

Volumn 6, Issue 2, 2010, Pages 88-101

  Romero Aroca, Pedro ^a,b   Mendez Marin, Isabel ^a   Baget Bernaldiz, Marc ^a   Fernández Ballart, Juan ^b   Santos Blanco, Ester ^a  

^a HOSPITAL UNIVERSITARI SANT JOAN DE REUS   (Spain)

^b UNIVERSITAT ROVIRA I VIRGILI   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ADVANCED GLYCATION END PRODUCT; ALDEHYDE REDUCTASE; ANGIOTENSIN II; CYTOKINE; GROWTH FACTOR; GROWTH HORMONE; PROTEIN KINASE C; SOMATOMEDIN C; TRANSFORMING GROWTH FACTOR BETA1; VASCULOTROPIN;

BIOCHEMISTRY; DIABETES MELLITUS; DIABETIC MICROANGIOPATHY; DIABETIC NEPHROPATHY; DIABETIC RETINOPATHY; DISEASE ASSOCIATION; HISTOPATHOLOGY; HUMAN; HYPERGLYCEMIA; INSULIN DEPENDENT DIABETES MELLITUS; MICROALBUMINURIA; NON INSULIN DEPENDENT DIABETES MELLITUS; PREDICTION; PRIORITY JOURNAL; QUALITY OF LIFE; RETINA MACULA EDEMA; REVIEW; SCREENING TEST;

AGED; AGED, 80 AND OVER; CHILD; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; DIABETIC NEPHROPATHIES; DIABETIC RETINOPATHY; HUMANS; MASS SCREENING; MIDDLE AGED; RISK FACTORS; YOUNG ADULT;

EID: 77950797377     PISSN: 15733998     EISSN: None     Source Type: Journal    
DOI: 10.2174/157339910790909387     Document Type: Review

References (122)

1. World Health Organization: Diabetes mellitus. Report of a WHO study group Geneva 1985; Technical Report Series No. 727.
2. The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Report of the expert committee on the diagnosis and classification of diabetes mellitus. Diabetes Care 2000; 23: S4-S19.
3. American Diabetes Association. Clinical practice recommendations. Diabetes Care 2002; 25: S1-S2.
4. Geiss L, Engelgau M, Fraizer E, Tierney E. Diabetes surveillance,. Centers for disease control and prevention. US departement of health and human services Atlanta GA. 1997.
5. Diabetes Control and Complications Trial Research Group. Progression of retinopathy with intensive versus conventional treatment in the diabetes control and complications trial. Ophthalmology 1995; 102: 647-661
6. Aldington SJ, Kohner EM, Meuer S, Klein R, Sjolie AK. Methodology for retinal photography and assessment of diabetic retinopathy: The EURODIAB IDDM complications study. Diabetologia 1995; 38: 437-444
7. Harding M, Lapuz S. Diabetic nephropathy. Med Clin North Am 1997; 81: 679-687
8. Brancati FL, Cusumano AM. Epidemiology and prevention of diabetic nephropathy. Curr Opin Nephrol Hypertens 1995; 4: 2239.
9. Jawa A, Kcomt J, Fonseca VA. Diabetic nephropathy and retinopathy. Med Clin North Am 2004; 88: 1001-1036
10. Klein R, Klein BEK, Moss SE, Cruickshanks KJ. The Wisconsin epidemiologic study of diabetic retinopathy: XVII. The 14-year incidence and progression of diabetic retinopathy and associated risk factors in type 1 diabetes. Ophthalmology 1998; 105: 1801-1815
11. Klein R, Klein BE, Moss SE, Cruickshanks KJ. The Wisconsin epidemiology study of diabetic retinopathy. XIV. Ten year incidence and progression of diabetic retinopathy. Arch Ophthalmol 1994; 112: 1217-1228
12. American Diabetes Association. Report of the expert committee on the diagnosis and classification of diabetes mellitus. Diabetes Care 1997; 20: 1183-1201
13. American Diabetes Association. Clinical practice recommendations. Diabetes Care 2002; 25: S1.
14. ETDRS. Detection of diabetic macular edema study no5. Ophthalmology 1989; 96: 746-751
15. Lee CM, Olk RJ. Modified grid laser photocoagulation for diffuse diabetic macular edema: long-term visual results. Ophthalmology 1991; 98: 1594-602.
16. Early Treatment Diabetic Retinopathy Study Research Group. Photocoagulation for diabetic macular edema. Int Ophthalmol Clin 1987; 27: 265-272
17. Rohan TE, Frost CD, Wald NJ. Prevention of blindness by screening for diabetic retinopathy: a quantitative assessment. BMJ 1989; 299: 1198-1201
18. Buxton MJ, Sculpher MJ, Ferguson BA, Humphreys JE, Altman JFB, Spiegelhalter DJ. Screening for treatable diabetic retinopathy: a comparison of different methods. Diabet Med 1991; 8: 371-377
19. Finlay R, Griffiths J, Jackson G, Law D. Can general practitioners screen their own patients for diabetic retinopathy? Health Trends 1991; 23: 104-105
20. Awh CC, Javitt JC, Chong LP, Gehrs KM, Gusman GI, Street DA. Ophthalmoscopic diagnosis and referral of diabetic eye disease by primary care physicians. ARVO abstract. Invest Ophthalmol Vis Sci 1993; 34: 713.
21. Gehrs KM, Chong LP, Guzman G, Street DA, Awh C, Cupples H. Can we educate primary care physicians about diabetic retinopathy after graduation? Preliminary results of the diabetic retinopathy education study. ARVO abstract. Invest Ophthalmol Vis Sci 1993; 34: 1182.
22. Herbert HM, Jordan K, Flanagan DW. Is screening with digital imaging using one retinal view adequate? Eye 2003; 17: 497-500.
23. Scanlon PH, Malhotra R, Thomas G, et al. The effectiveness of screening for diabetic retinopathy by digital imaging photography and technician ophthalmoscopy. Diabetic Med 2003; 20: 467-474 (Pubitemid 36776007)
24. Buxton MJ, Sculpher MJ, Ferguson BA, et al. Screening for treatable diabetic retinopathy: A comparison of different methods. Diabetic Med 1991; 8: 371-377
25. Harding SP, Broadbent DM, Neon C, White MC, Vora J. Sensitivity and specificity of photography and direct ophthalmoscopy in screening for sight threatening eye disease: The Liverpool diabetic eye study. BMJ 1995; 311: 1131-1135
26. Heaven CJ, Cansfield J, Shaw KM. The quality of photographs produced by the non-mydriatic fundus camera in a screening programme for diabetic retinopathy: a 1-year prospective study. Eye 1993; 7: 787-790
27. Romero-Aroca P, Fernandez-Balart J, Baget-Bernaldiz M, et al. Changes in the diabetic retinopathy epidemiology after 14 years in a population of Type 1 and 2 diabetic patients after the new diabetes mellitus diagnosis criteria and a more strict control of the patients. J Diabetes Comp 2008; 23: 229-238
28. Mogensen CE, Christensen CK, Vittinghus E. The stages in diabetic renal disease, with emphasis on the stage of incipient diabetic nephropathy. Diabetes 1983; 32: 64-78.
29. Grading diabetic retinopathy from stereoscopic color fundus photographs - an extension of the modified Airlie House classification: ETDRS Report No. 10. Ophthalmology 1991; 98(suppl 5): 786806.
30. Wilkinson CP, Ferris FL, III, Klein RE, et al. Global Diabetic Retinopathy Project Group. Proposed international clinical diabetic retinopathy and diabetic macular edema disease severity scales. Ophthalmology 2003; 110: 1677-1682
31. Schwartz MM, Lewis EJ, Leonard-Martin TH, Breyer LJ, Batlle D and the Collaborative Study Group. Renal pathology patterns in type II diabetes mellitus: relationship with retinopathy. Nephrol Dial Transplant 1998; 13: 2547-2552
32. Parving HH, Mogensen CE, Thomas MC, Brenner BM, Cooper ME. Poor prognosis in proteinuric type 2 diabetic patients with retinopathy: insights from the RENAAL study. QJM 2005; 98: 119-126
33. Hammes HP, Du X, Edelstein D, Taguchi T, Matsumura T, Ju Q. Benfotiamine blocks three major pathways of hyperglycemic damage and prevents experimental diabetic retinopathy. Nat Med 2003; 9: 294-299
34. Neely KA, Quillen DA, Schachat AP, Gardner TW, Blankenship GW. Diabetic retinopathy. Med Clin North Am 1998; 82: 847-876
35. Brownlee M. Biochemistry and molecular cell biology of diabetic complications. Nature 2001; 414: 813-820
36. Way KJ, Katai N, King GL. Protein kinase C and the development of diabetic vascular complications. Diabetic Med 2001; 18: 945-959
37. Cooper ME. Pathogenesis, prevention, and treatment of diabetic nephropathy. Lancet 1998 18; 352: 213-219
38. Craven PA, DeRubertis FR. Protein kinase C is activated in glome- ruli from streptozotocin diabetic rats: possible mediation by glucose. J Clin Investig 1989; 83: 1667-1675
39. Chen S, Cohen MP, Lautenslager GT, Shearman CW, Ziyadeh FN. Glycated albumin stimulates TGF-beta 1 production and proteinkinase C activity in glomerular endothelial cells. Kidney Int 2001; 59: 673-681
40. Koya D, King GL. Protein kinase C activation and the development of diabetic complications. Diabetes 1998; 47: 859-866
41. Koya D, Jirousek MR, Lin YW, Ishii H, Kuboki K, King GL. Characterization of protein kinase C beta isoform activation on the gene expression of transforming growth factor-beta, extracellular matrix components, and prostanoids in the glomeruli of diabetic rats. J Clin Investig 1997; 100: 115-126
42. Koya D, Lee IK, Ishii H, Kanoh H, King GL. Prevention of glome- rular dysfunction in diabetic rats by treatment with d-alphatocopherol. J Am Soc Nephrol 1997; 8: 426-435
43. Ishii H, Jirousek MR, Koya D, et al. Amelioration of vascular dysfunctions in diabetic rats by an oral PKC beta inhibitor. Science 1996; 272: 728-731
44. Frank RN. The aldose reductase controversy. Diabetes 1994; 43: 169-172
45. Delahanty LM, Nathan DM, Lachin JM, et al. Diabetes Control and Complications Trial/Epidemiology of Diabetes. Association of diet with glycated hemoglobin during intensive treatment of type 1 diabetes in the diabetes control and complications trial. Am J Clin Nutr 2009; 89: 518-524
46. Stratton IM, Kohner EM, Aldington SJ, et al. UKPDS risk factors for incidence and progression of retinopathy in Type II diabetes over 6 years from diagnosis. Diabetologia 2001; 44: 156-163
47. Brownlee M. Advanced protein glycosylation in diabetes and aging. Ann Rev Med 1995; 46: 223-234
48. Yamagishi S, Takeuchi M, Inagaki Y, Nakamura K, Imaizumi T. Role of advanced glycation end products (AGEs) and their receptor (RAGE) in the pathogenesis of diabetic microangiopathy. Int J Clin Pharmcol Res 2003; 23: 129-134
49. Matsumura T, Yamagishi S, Brownlee M. In: LD, Taylor SI, Olefsky JM, Eds. Advanced glycation end products and the pathogene- sis of diabetic complications. Diabetes mellitus: a fundamental and clinical text. New York: Lippincott-Raven Publishers, 2000; pp. 983-991
50. Takeuchi M, Yamagishi S. Alternative routes for the formation of glyceraldehyde-derived AGEs (TAGE) in vivo. Med Hypotheses 2004; 63: 453-455
51. Stitt AW, Li YM, Gardiner TA, Bucala R, Archer DB, Vlassara H. Advanced glycation end products (AGEs) co-locarize with AGE receptors in the retinal vasculature of diabetic and AGE-infused rats. Am J Pathol 1997; 150: 523-531
52. Sharma NK, Gardiner TA, Archer DB. A morphologic and autoradiographic study of cell death and regeneration in the retinal mi- crovasculature of normal and diabetic rats. Am J Ophthalmol 1985; 100: 51-60.
53. Miura J, Yamagishi S, Uchigata Y, et al. Serum levels of noncarboxymethyllysine advanced glycation endproducts are correlated to severity of microvascular complications in patients with Type 1 diabetes. J Diabetes Complications 2003; 17: 16-21.
54. Koga K, Yamagishi S, Okamoto T, et al. Serum levels of glucose derived advanced glycation end products are associated with the severity of diabetic retinopathy in type 2 diabetic patients without renal dysfunction. Int J Clin Pharmacol Res 2002; 22: 13-17.
55. de Vriese AS, Tilton RG, Elger M, Stephan CC, Kriz W, Lameire NH. Antibodies against vascular endothelial growth factor improve early renal dysfunction in experimental diabetes. J Am Soc Nephrol 2001; 12: 993-1000.
56. Yamagishi S, Inagaki Y, Okamoto T, Amano S, Koga K, Takeuchi M. Advanced glycation end products inhibit de novo protein synthesis and induce TGF-beta overexpression in proximal tubular cells. Kidney Int 2003; 63: 464-473
57. Kato S, Luyckx VA, Ots M. Renin-angiotensin blockade lowers MCP-1 expression in diabetic rats. Kidney Int 1999; 56: 1037-1048
58. Okada S, Shikata K, Ogawa D. Critical role of macrophage in the progression of diabetic nephropathy revealed by ICAM-1 knockout mice. Diabetes 2001; 50: 256.
59. Utimura R, Fujihara CK, Mattar AL, Malheiros DM, Noronha IL, Zatz R. Mycophenolate mofetil prevents the development of glomerular injury inexperimental diabetes. Kidney Int 2003; 63: 209-216 (Pubitemid 35463923)
60. Ihm CG, Park JK, Hong SP, et al. A high glucose concentration stimulates the expression of monocyte chemotactic peptide 1 in human mesangial cells. Nephron 1998; 79: 33-37
61. Schroder S, Palinski W, Schmid-Schobein GW. Activated monocytes and granulocytes, capillary nonperfusion and neovascularization in diabetic retinopathy. Am J Pathol 1991; 139: 81-100.
62. Knott RM, Robertson M, Muckersie E. A model study for the study of human retinal angiogenesis: activation of monocytes and endothelial cells and the association with the expression of the monocarboxylate transporter type 1 (MCT-1). Diabetologia 1999; 42: 870-877
63. Esser P, Heimann K, Wiedemann P. Macrophages in proliferative vitreoretinopathy and proliferative diabetic retinopathy. Differentiation of subpopulations. Br J Ophthalmol 1993; 77: 731-733 (Pubitemid 23326062)
64. Matsushima K, Larsen CG, DuBois GC, Oppenheim JJ. Purification and characterization of a novel monocyte chemotactic and activating factor produced by a human myelomonocytic cell line. J Exp Med 1989; 169: 1485-1490
65. Rollins BJ, Walz A, Baggiolini M. Recombinant human MCP-1/JE induces chemotaxis, calcium flux, and the respiratory burst in human monocytes. Blood 1991; 78: 1112-1116
66. Elner SG, Elner VM, Jaffe GJ, Stuart A, Kunkel SL, Strieter RM. Cytokines in proliferative diabetic retinopathy and proliferative vit- reoretinopathy. Curr Eye Res 1995; 14: 1045-1053
67. Capeans C, Victoria de Rojas M, Lojo S, Salorio MS. C-C chemokines in the vitreous of patients with prolferative vitreore- tionpathy and preliferative diabetic retinopathy. Retina 1998; 18: 546-550
68. Abu el-Asrar AM, Van Damme J, Put W, et al. Monocyte chemotactic protein-1 in proliferative vitreoretinal disorders. Am J Ophthalmol 1997; 123: 599-606.
69. Bavbek N, Kargili A, Kaftan O, Karakurt F, Kosar A, Alkcay A. Elevated concentrations of soluble adhesion molecules and large platelets in diabetic patients: are they markers of vascular disease and diabetic nephropathy. Clin Appl Thromb Hemost 2007; 13: 391-397
70. Abu El-Asrar AM, Maimone D, Morse PH, Gregory S, Reder AT. Cytokines in the vitreous of patients with proliferative diabetic retinopathy. Am J Ophthalmol 1992; 114: 731-736
71. Funatsu H, Yamashita H, Shimizu E, Kojima R, Hori S. Relationship between vascular endothelial growth factor and interleukin-6 in diabetic retinopathy. Retina 2001; 21: 469-477
72. Elner SG, Strieter R, Bian ZM, et al. Interferon-induced protein 10 and interleukin 8. C-X-C chemokines present in proliferative diabetic retinopathy. Arch Ophthalmol 1998; 116: 1597-1601
73. Yuuki T, Kanda T, Kimura Y, et al. Inflammatory cytokines in vitreous fluid and serum of patients with diabetic vitreoretinopathy. J Diabetes Complications 2001; 15: 257-259 (Pubitemid 32750613)
74. Barile GR, Chang SS, Park LS, Reppucci VS, Schiff WM, Schmidt AM. Soluble cellular adhesion molecules in proliferative vitreoreti- nopathy and proliferative diabetic retinopathy. Curr Eye Res 1999; 19: 219-227
75. Limb GA, Hickman-Casey J, Hollifield RD, Chignell AH. Vascular adhesion molecules in vitreous from eyes with proliferative diabetic retinopathy. Invest Ophthalmol Vis Sci 1999; 40: 2453-2457
76. Hernandez C, Burgos R, Canton A, Garcia-Arumi J, Segura RM, Simo R. Vitreous levels of vascular cell adhesion molecule and vascular endothelial growth factor in patients with proliferative diabetic retinopathy: a case-control study. Diabetes Care 2001; 24: 516-521
77. Persson F, Rossing P, Hovind P, et al. Endothelial dysfunction and inflammation predict development of diabetic nephropathy in the Irbesartan in Patients with Type 2 diabetes and Microalbuminuria (IRMA 2) study. Scand J Clin Lab Invest 2008; 68: 731-738
78. Ziyadeh FN, Han DC. Involvement of TGF-p and its receptors in the pathogenesis of diabetic nephropathy. Kidney Int 1997; 52: S7-S11.
79. Yevdokimova N, Wahab NA, Mason RM. Thrombospondin-1 is the key activator of TGF-β in human mesangial cells exposed to high glucose. J Am Soc Nephrol 2001; 12: 703-712
80. Isono M, Mogyorosi A, Han DC, Hoffman BB, Ziyadeh FN. Stimulation of TGF-B type II receptor by high glucose in mouse mesangial cells and in diabetic kidney. Am J Physiol Renal Physiol 2000; 278: 830-838
81. Hayashida T, Schnaper HW. High ambient glucose enhances sensitivity to TGF-B 1 via extracellular signal-regulated kinase and protein kinase C activities in human mesangial cells. J Am Soc Neph- rol 2004; 15: 2032-2041
82. Ziyadeh FN, Sharma K, Ericksen M, Wolf G. Stimulation of collagen gene expression and protein synthesis in murine mesangial cells by high glucose is mediated by autocrine activation of transforming growth factor-beta. J Clin Investig 1994; 93: 536-542
83. Riser BL, Cortes P, Heilig C, et al. Cyclic stretching force selectively up regulates transforming growth factor-p. isoforms in cultured rat mesangial cells. Am J Pathol 1996; 148: 1915-1923
84. Mitamura Y, Tashimo A, Nakamura Y, et al. Vitreous levels of placenta growth factor and vascular endothelial growth factor in patients with proliferative diabetic retinopathy. Diabetes Care 2002; 25: 2352.
85. Ishida S, Shinoda K, Kawashima S, Oguchi Y, Okada Y, Ikeda E. Coexpression of VEGF receptors VEGF-R2 and neuropilin-1 in proliferative diabetic retinopathy. Invest Ophthalmol Vis Sci 2000; 41: 1649-1656
86. Mak RH, Cheung WW, Roberts CT, Jr. The growth hormone-insulin-like growth factor-I axis in chronic kidney disease. Growth Horm IGF Res 2008; 18: 17-25.
87. Clemmons DR. Involvement of insulin-like growth factor-I in the control of glucose homeostasis. Curr Opin Pharmacol 2006; 6: 6205.
88. Feldt-Rasmussen B, El Nahas M. Potential role of growth factors with particular focus on growth hormone and insulin-like growth factor-1 in the management of chronic kidney disease. Semin Nephrol 2009; 29: 50-58
89. Chestnut RE, Quarmby V. Evaluation of total IGF-I assay methods using samples from Type I and Type II diabetic patients. J Immunol Methods 2002; 259: 11-24.
90. Flyvbjerg A. Putative pathophysiological role of growth factors and cytokines in experimental diabetic kidney disease. Diabetologia 2000; 43: 1205-1223
91. Viberti G, Wheeldon NM. Microalbuminuria reduction with valsar- tan (MARVAL) study investigators: microalbuminuria reduction with valsartan in patients with type 2 diabetes mellitus: a blood pressure-independent effect. Circulation 2002;106: 672-678
92. Parving HH, Persson F, Lewis JB, Lewis EJ, Hollenberg NK. Al- iskiren combined with losartan in type 2 diabetes and nephropathy. N Engl J Med 2008; 358: 2433-2446
93. Kim JH, Kim JH, Yu YS, Cho CS, Kim KW. Blockade of angiotensin II attenuates VEGF-mediated blood-retinal barrier breakdown in diabetic retinopathy. J Cereb Blood Flow Metab 2009; 29: 621-628
94. Hansson L, Lindholm LH, Niskanen L, et al. Effect of angiotensin- converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the captopril prevention project (CAPPP) randomised trial. Lancet 1999; 353: 611-616 (Pubitemid 29087980)
95. Chaturvedi N, Sjolie AK, Stephenson JM, et al. Effect of lisinopril on progression of retinopathy in normotensive people with type 1 diabetes. The EUCLID Study Group. EURODIAB Controlled trial of lisinopril in insulin-dependent diabetes mellitus. Lancet 1998; 351: 28-31.
96. Orchard TJ, Dorman JS, Maser RE, et al. Prevalence of complications in IDDM by sex and duration. Pittsburgh epidemiology of diabetes complications study II. Diabetes 1990; 39: 1116-1124
97. Parving HH, Hommel E, Mathiesen E, et al. Prevalence of micro- albuminuria, arterial hypertension, retinopathy and neuropathy in patients with insulin dependent diabetes. BMJ 1988; 296: 156-160
98. Ng LL, Davies JE, Siczkowski M, et al. Abnormal Na+/H+ an- tiporter phenotype and turnover of immortalized lymphoblasts from type 1 diabetic patients with nephropathy. J Clin Investig 1994; 93: 2750-2757
99. The ACE Inhibitors in Diabetic Nephropathy Trialist Group. Should all patients with type 1 diabetes mellitus and microalbu- minuria receive angiotensin-converting enzymeinhibitors? A metaanalysis of individual patient data. Ann Intern Med 2001; 134: 3709.
100. Parving HH, Gall MA, Sk0tt P, et al. Prevalence and causes of albuminuria in non-insulin-dependent diabeticpatients. Kidney Int 1992; 41: 758-762
101. Christensen PK, Larsen S, Horn T, Olsen S, Parving HH. Renal function and structure in albuminuric type 2 diabetic patients without retinopathy Nephrol Dial Transplant 2001; 16: 2337-2347
102. Kofoed-Enevoldsen A, Jensen T, Borch-Johnsen K, Deckert T. Incidence of retinopathy in type 1 (insulin-dependent) diabetes: association with clinical nephropathy. J Diabet Complications 1987; 1: 96-99
103. Klein R, Moss SE, Klein BE. Is gross proteinuria a risk factor for the incidence of proliferative diabetic retinopathy? Ophthalmology 1993; 100: 1140-1146
104. El-Asrar AM, Al-Rubeaan KA, Al-Amor SA, Moharram OA, Kangave D. Retinopathy as a predictor of other diabetic complications. International Ophthalmology 2002; 24: 1-11.
105. Stephenson JM, Fuller JH, Viberti G, Sjolie AK, The EURODIAB IDDM Complications Study Group. Blood pressure, retinopathy and urinary albumin excretion in IDDM: The EURODIAB IDDM Complications Study. Diabetologia 1995; 38: 599-603.
106. Romero P, Salvat M, Fernandez J, Baget M, Martinez I. Renal and retinal microangiopathy after 15 years follow-up study in a sample of type I diabetes mellitus patients. J Diabetic Complications 2007; 21: 93-100.
107. Romero P , Baget M, Mendez I , Fernandez J, Salvat M , Martinez I. Diabetic macular oedema and its relationship to renal microangiopathy: a sample of type I diabetes mellitus patients in a 15 years follow-up study. J Diabetic Complications 2007; 21: 172-180 (Pubitemid 46711079)
108. Mogensen CE, Vigstrup J, Elhers N. Microalbuminuria predicts proliferative diabetic retinopathy. Lancet 1985; 1: 1512-1513
109. Barnett AM, Dallinger K, Jennings P. Microalbuminuria predicts proliferative diabetic retinopathy. Lancet 1985; 1: 1512-1513
110. Rossing P, Hougaard P, Parving H. Risk factors for development of incipient and overt diabetic nephropathy in type 1 diabetic patients: A 10-year prospective observational study. Diabetes Care 2002; 25: 859-864
111. Schmechel H, Heinrich U. Retinopathy and nephropathy in insulin-treated diabetic patients in relation to the type of diabetes. Diabetes Metabolism 1993; 19: 138-142
112. Parving HH, Hommel E, Mathiesen E, et al. Prevalence of microalbuminuria, arterial hypertension, retinopathy and neuropathy in patients with insulin dependent diabetes. BMJ 1988; 296: 156-160
113. Romero Aroca P, Calviño Dominguez O, Del Castillo Dejardin D. Epidemiologic study of diabetic retinopathy in a primary care unit. Arch Soc Esp Oftalmol 2000; 75: 147-152
114. Romero-Aroca P, Salvat M, Fernandez J, Mendez I. Risk factors for diffuse and focal macular edema. J Diabetic Complications 2004; 18: 211-215
115. Billaut BM, Passa, PL. Factors associated with diabetic microangiopathy: A study of 157 type 1 (insulin-dependent) diabetic patients. J Diabetic Complications 1991, 5: 238-243
116. Lofvestam-Adrian M, Agardh E, Agardh CD. The temporal development of retinopathy and nephropathy in type 1 diabetes mellitus during 15 years diabetes duration. Diabetes Res Clin Pract 1999, 45: 15-23.
117. Parving H-H, Gall M-A, Skøtt P, et al. Prevalence and causes of albuminuria in non-insulin-dependent diabetic patients. Kidney Int 1992; 41: 758-762
118. Schwartz MM, Lewis EJ, Leonard-Martin T, Breyer-Lewis J, Battle D, The Collaborative Study Group. Renal pathology patterns in type II diabetes mellitus: Relationship with retinopathy. Nephrol Dial Transplant 1998; 13: 2547-2552
119. Fioretto P, Mauer SM, Brocco E, et al. Patterns of renal injury in NIDDM patients with microalbuminuria. Diabetologia 1996; 39: 1569-1576
120. Brocco E, Fioretto P, Mauer SM, et al. Renal structure and function in non-insulin dependent diabetic patients with microalbuminuria. Kidney Int 1997 52: S40-S4.
121. Christensen PK, Larsen S, Horn T, Olsen S, Parving HH. Causes of albuminuria in patients with type 2 diabetes without diabetic retinopathy. Kidney Int 2000; 58: 1719-1731
122. Christensen PK, Larsen S, Horn T, Olsen S, Parving HH. Renal function and structure in albuminuric type 2 diabetic patients without retinopathy. Nephrol Dial Transplant 2001; 16: 2337-2347